FULCRUM THERAPEUTICS INC's ticker is FULC and the CUSIP is 359616109. A total of 68 filers reported holding FULCRUM THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $14,284,831 | -55.4% | 1,962,202 | -50.5% | 11.20% | -20.0% |
| Q3 2022 | $32,054,000 | +65.1% | 3,962,202 | 0.0% | 14.00% | +76.2% |
| Q2 2022 | $19,415,000 | -79.3% | 3,962,202 | 0.0% | 7.94% | -68.8% |
| Q1 2022 | $93,706,000 | +33.7% | 3,962,202 | 0.0% | 25.43% | +45.0% |
| Q4 2021 | $70,091,000 | -49.9% | 3,962,202 | -20.2% | 17.54% | -34.0% |
| Q3 2021 | $139,984,000 | +124.0% | 4,962,202 | -16.8% | 26.57% | +143.6% |
| Q2 2021 | $62,484,000 | -11.0% | 5,962,202 | 0.0% | 10.91% | +22.8% |
| Q1 2021 | $70,235,000 | +0.6% | 5,962,202 | 0.0% | 8.88% | +48.2% |
| Q4 2020 | $69,817,000 | +47.7% | 5,962,202 | 0.0% | 6.00% | +51.0% |
| Q3 2020 | $47,280,000 | -56.6% | 5,962,202 | 0.0% | 3.97% | -75.1% |
| Q2 2020 | $109,049,000 | +53.2% | 5,962,202 | 0.0% | 15.92% | -17.8% |
| Q1 2020 | $71,189,000 | -28.2% | 5,962,202 | 0.0% | 19.37% | -55.8% |
| Q4 2019 | $99,211,000 | +150.6% | 5,962,202 | 0.0% | 43.81% | +95.3% |
| Q3 2019 | $39,589,000 | – | 5,962,202 | – | 22.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP III, LLC | 3,962,202 | $19,415,000 | 7.94% |
| TRV GP IV, LLC | 2,343,154 | $11,481,000 | 7.55% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 949 | $193,741,000 | 2.02% |
| Logos Global Management LP | 1,950,000 | $9,555,000 | 1.75% |
| COWEN AND COMPANY, LLC | 2,385,885 | $11,691,000 | 1.13% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,355,624 | $16,443,000 | 0.62% |
| ACUTA CAPITAL PARTNERS, LLC | 200,000 | $980,000 | 0.55% |
| RTW INVESTMENTS, LP | 3,961,194 | $19,410,000 | 0.50% |
| Parkman Healthcare Partners LLC | 262,689 | $1,287,000 | 0.47% |
| Deep Track Capital, LP | 1,000,000 | $4,900,000 | 0.32% |